Related Experiment Video
Updated: Jun 8, 2026

Stereotactic Atlas-Guided Laser Capture Microdissection of Brain Regions Affected by Traumatic Injury
Published on: September 11, 2017
Human traumatic brain injury alters plasma microRNA levels
John B Redell1, Anthony N Moore, Norman H Ward
1Department of Neurobiology and Anatomy, The University of Texas Health Science Center at Houston, Houston, Texas, USA.
Abstract:
Circulating microRNAs (miRNAs) present in the serum/plasma are characteristically altered in many pathological conditions, and have been employed as diagnostic markers for specific diseases. We examined if plasma miRNA levels are altered in patients with traumatic brain injury (TBI) relative to matched healthy volunteers, and explored their potential for use as diagnostic TBI biomarkers. The plasma miRNA profiles from severe TBI patients (Glasgow Coma Scale [GCS] score ≤8) and age-, gender-, and race-matched healthy volunteers were compared by microarray analysis. Of the 108 miRNAs identified in healthy volunteer plasma, 52 were altered after severe TBI, including 33 with decreased and 19 with increased relative abundance. An additional 8 miRNAs were detected only in the TBI plasma. We used quantitative RT-PCR to determine if plasma miRNAs could identify TBI patients within the first 24 h post-injury. Receiver operating characteristic curve analysis indicated that miR-16, miR-92a, and miR-765 were good markers of severe TBI (0.89, 0.82, and 0.86 AUC values, respectively). Multiple logistic regression analysis revealed that combining these miRNAs markedly increased diagnostic accuracy (100% specificity and 100% sensitivity), compared to either healthy volunteers or orthopedic injury patients. In mild TBI patients (GCS score > 12), miR-765 levels were unchanged, while the plasma levels of miR-92a and miR-16 were significantly increased within the first 24 h of injury compared to healthy volunteers, and had AUC values of 0.78 and 0.82, respectively. Our results demonstrate that circulating miRNA levels are altered after TBI, providing a rich new source of potential molecular biomarkers. Plasma-derived miRNA biomarkers, used in combination with established clinical practices such as imaging, neurocognitive, and motor examinations, have the potential to improve TBI patient classification and possibly management.
Insights
Plasma microRNAs (miRNAs) show altered levels in traumatic brain injury (TBI) patients. Specific miRNAs, like miR-16 and miR-92a, show promise as diagnostic biomarkers for TBI, improving patient classification.
Area of Science:
- Biochemistry
- Molecular Biology
- Neuroscience
Background:
- Circulating microRNAs (miRNAs) in serum/plasma are altered in various pathological conditions.
- These miRNAs have potential as diagnostic markers for specific diseases.
- Traumatic brain injury (TBI) is a significant health concern with a need for improved diagnostic tools.
Purpose of the Study:
- To investigate alterations in plasma miRNA levels in patients with TBI compared to healthy controls.
- To explore the potential of plasma miRNAs as diagnostic biomarkers for TBI.
- To assess the diagnostic accuracy of specific miRNAs for identifying TBI patients.
Main Methods:
- Plasma miRNA profiles were analyzed using microarray analysis in severe TBI patients and matched healthy volunteers.
- Quantitative RT-PCR was employed to validate miRNA levels within 24 hours post-injury.
- Receiver operating characteristic (ROC) curve analysis and logistic regression were used to assess diagnostic potential.
Main Results:
- Significant alterations in plasma miRNA levels were observed in severe TBI patients, with 52 out of 108 identified miRNAs showing changed abundance.
- miR-16, miR-92a, and miR-765 demonstrated good diagnostic accuracy for severe TBI (AUCs 0.89, 0.82, 0.86).
- Combining these miRNAs achieved 100% sensitivity and specificity for TBI diagnosis. Mild TBI showed increased miR-92a and miR-16 levels.
Conclusions:
- Circulating plasma miRNA levels are significantly altered following TBI.
- Specific plasma miRNAs, particularly miR-16, miR-92a, and miR-765, serve as promising molecular biomarkers for TBI diagnosis.
- These miRNA biomarkers, when used with clinical assessments, can enhance TBI patient classification and management.

